MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 8.7% Higher – Here’s What Happened

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s stock price traded up 8.7% on Tuesday . The company traded as high as $18.38 and last traded at $18.4090. 127,881 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 1,925,307 shares. The stock had previously closed at $16.93.

More MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: BTIG reaffirmed its Buy rating on MoonLake, keeping institutional support that can attract momentum investors. BTIG Research Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
• Positive Sentiment: H.C. Wainwright reiterated a Buy on MLTX and continues to use a $40 price target, reinforcing a favorable sell‑side view and a high upside reference point for investors. H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
• Positive Sentiment: MLTX has drawn retail attention from buyout speculation and release of positive skin‑condition trial data — a near‑term catalyst that likely lifted volume and interest even as volatility increased. MLTX stock garners retail attention on buyout speculation, positive skin condition trial data
• Neutral Sentiment: H.C. Wainwright published quarterly EPS forecasts for 2027 (Q1–Q4) showing continued per‑share losses (e.g., quarterly EPS guides around -$0.70 to -$0.91) while maintaining its Buy stance — useful for modeling near‑term cash burn but not a rating change. HC Wainwright estimates for MoonLake Immunotherapeutics (MarketBeat)
• Neutral Sentiment: MarketWatch’s cash‑flow/financials page provides the company’s liquidity metrics and financials that investors should review — MoonLake shows ample current/quick ratios and modest leverage, which may support runway. MoonLake Immunotherapeutics cash flow (MarketWatch)
• Negative Sentiment: MoonLake reported continuing GAAP losses (recent quarter EPS ~ -$0.92, matching estimates but worse year‑over‑year) and the street expects full‑year negative EPS — a reminder that the company is not yet profitable and remains dependent on funding or positive clinical outcomes. MoonLake financial summary and analyst consensus (MarketBeat)

Analysts Set New Price Targets

A number of research analysts recently issued reports on MLTX shares. Needham & Company LLC boosted their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, February 23rd. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their target price for the stock from $8.00 to $10.00 in a report on Wednesday, January 14th. Royal Bank Of Canada lifted their price target on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $12.00 to $40.00 in a report on Thursday, March 19th. Finally, Zacks Research upgraded shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $23.08.

MoonLake Immunotherapeutics Price Performance

The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.24. The company has a fifty day moving average price of $16.91 and a two-hundred day moving average price of $16.88. The firm has a market cap of $1.18 billion, a P/E ratio of -4.69 and a beta of 1.19.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.92). During the same period in the prior year, the firm earned ($0.72) EPS. Equities analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MLTX. Principal Financial Group Inc. bought a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $509,000. Decheng Capital LLC bought a new position in shares of MoonLake Immunotherapeutics during the second quarter worth about $8,572,000. Rhenman & Partners Asset Management AB grew its holdings in shares of MoonLake Immunotherapeutics by 360.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 207,000 shares of the company’s stock worth $1,484,000 after buying an additional 162,000 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in MoonLake Immunotherapeutics by 22,387.5% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company’s stock valued at $606,000 after buying an additional 84,177 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $1,792,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.